Track topics on Twitter Track topics that are important to you
Immune Pharmaceuticals (OTCQB:IMNP) has announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on its application for Orphan Drug Designation for bertilimumab for treating bullous pemphigoid (BP). As quoted in the press release: “We are pleased that the COMP has issued its opinion in … Continued
The post Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for Bertilimumab for the Treatment of Bullous Pemphigoid appeared first on Investing News Network.NEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...